chitosan has been researched along with fingolimod hydrochloride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choudhury, SR; Karmakar, S; Sardoiwala, MN | 1 |
| Abbaspour-Ravasjani, S; Bani, F; Beyrampour-Basmenj, H; Ebrahimi-Kalan, A; Gao, H; Ghadiri, T; Khodakarimi, S; Rahbarghazi, R; Sadeghi, MR; Seidi, K; Sepasi, T; Talebi, M; Zarebkohan, A | 1 |
2 other study(ies) available for chitosan and fingolimod hydrochloride
| Article | Year |
|---|---|
Chitosan nanocarrier for FTY720 enhanced delivery retards Parkinson's disease via PP2A-EzH2 signaling in vitro and ex vivo.
Topics: alpha-Synuclein; Animals; Biological Availability; Cell Line, Tumor; Chitosan; Disease Models, Animal; Drug Carriers; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Fingolimod Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Neurons; Neuroprotective Agents; Parkinson Disease; Phosphorylation; Protein Aggregates; Protein Phosphatase 2; Proteolysis; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators; Ubiquitination | 2021 |
CDX-modified chitosan nanoparticles remarkably reduce therapeutic dose of fingolimod in the EAE model of mice.
Topics: Animals; Chitosan; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Mice; Mice, Inbred C57BL; Nanoparticles; T-Lymphocytes | 2023 |